Corbus Pharmaceuticals Holdings, Inc. (CRBP)

NASDAQ: CRBP · IEX Real-Time Price · USD
37.16
-3.96 (-9.63%)
At close: Apr 17, 2024, 4:00 PM
37.20
+0.04 (0.11%)
After-hours: Apr 17, 2024, 6:27 PM EDT
-9.63%
Market Cap 389.92M
Revenue (ttm) n/a
Net Income (ttm) -44.60M
Shares Out 10.49M
EPS (ttm) -10.31
PE Ratio n/a
Forward PE n/a
Dividend n/a
Ex-Dividend Date n/a
Volume 419,730
Open 40.63
Previous Close 41.12
Day's Range 36.09 - 41.12
52-Week Range 3.03 - 49.87
Beta 2.47
Analysts Strong Buy
Price Target 52.00 (+39.94%)
Earnings Date May 7, 2024

About CRBP

Corbus Pharmaceuticals Holdings, Inc., a biopharmaceutical company, develops products to defeat serious illness. It develops CRB-701, an antibody drug conjugate (ADC) that targets the expression of Nectin-4 on cancer cells to release a cytotoxic payload of monomethyl auristatin E (MMAE), which is in Phase I clinical trial; CRB-601, an anti-integrin monoclonal antibody that blocks the activation of TGFß expressed on cancer cells for the treatment of solid tumors; CRB-913, a peripherally restricted cannabinoid type-1 (CB1) receptor inverse agonis... [Read more]

Industry Biotechnology
Sector Healthcare
Founded 2009
Employees 19
Stock Exchange NASDAQ
Ticker Symbol CRBP
Full Company Profile

Financial Performance

Financial Statements

Analyst Forecast

According to 2 analysts, the average rating for CRBP stock is "Strong Buy." The 12-month stock price forecast is $52.0, which is an increase of 39.94% from the latest price.

Price Target
$52.0
(39.94% upside)
Analyst Consensus: Strong Buy
Stock Forecasts

News

Corbus Announces Dosing of First Patient in U.S. Phase 1 Clinical Trial of Its Next Generation Nectin-4 Targeting ADC

NORWOOD, Mass., April 02, 2024 (GLOBE NEWSWIRE) -- Corbus Pharmaceuticals Holdings, Inc. (NASDAQ: CRBP) (“Corbus” or the “Company”), a precision oncology company with a diversified portfolio, announce...

15 days ago - GlobeNewsWire

Corbus Pharmaceuticals Reports Fourth Quarter and Year-End 2023 Financial Results and Provides Corporate Update

NORWOOD, Mass., March 12, 2024 (GLOBE NEWSWIRE) -- Corbus Pharmaceuticals Holdings, Inc. (NASDAQ: CRBP) (“Corbus” or the “Company”), a precision oncology company with a diversified portfolio, today pr...

5 weeks ago - GlobeNewsWire

Corbus Pharmaceuticals to Participate in the BMO Capital Markets Inaugural Obesity Summit

NORWOOD, Mass., March 06, 2024 (GLOBE NEWSWIRE) -- Corbus Pharmaceuticals Holdings, Inc. (NASDAQ: CRBP) (“Corbus” or the “Company”), today announced that Yuval Cohen, Ph.D., Chief Executive Officer of...

6 weeks ago - GlobeNewsWire

Corbus Pharmaceuticals Appoints Dr. Dominic Smethurst as Chief Medical Officer

NORWOOD, Mass., Feb. 28, 2024 (GLOBE NEWSWIRE) -- Corbus Pharmaceuticals Holdings, Inc. (NASDAQ: CRBP) (“Corbus” or the “Company”), a precision oncology company with a diversified portfolio, today ann...

7 weeks ago - GlobeNewsWire

Corbus Pharmaceuticals to Present at the Oppenheimer 34th Annual Healthcare Life Sciences Conference

NORWOOD, Mass., Feb. 06, 2024 (GLOBE NEWSWIRE) -- Corbus Pharmaceuticals Holdings, Inc. (NASDAQ: CRBP) (“Corbus” or the “Company”), today announced that Yuval Cohen, Ph.D., Chief Executive Officer of ...

2 months ago - GlobeNewsWire

Corbus Pharmaceuticals Announces Closing of $94.5 Million Public Offering of Common Stock including Full Exercise of Underwriters' Option to Purchase Additional Shares

NORWOOD, Mass., Feb. 02, 2024 (GLOBE NEWSWIRE) -- Corbus Pharmaceuticals Holdings, Inc. (Nasdaq: CRBP) (“Corbus” or the “Company”), a precision oncology company with a diversified portfolio, today ann...

2 months ago - GlobeNewsWire

Corbus Pharmaceuticals Announces Pricing of Public Offering

NORWOOD, Mass., Jan. 31, 2024 (GLOBE NEWSWIRE) -- Corbus Pharmaceuticals Holdings, Inc. (Nasdaq: CRBP) (“Corbus” or the “Company”), a precision oncology company with a diversified portfolio, today ann...

2 months ago - GlobeNewsWire

Corbus Pharmaceuticals Announces Proposed Public Offering

NORWOOD, Mass., Jan. 30, 2024 (GLOBE NEWSWIRE) -- Corbus Pharmaceuticals Holdings, Inc. (Nasdaq: CRBP) (“Corbus” or the “Company”), a precision oncology company with a diversified portfolio, today ann...

2 months ago - GlobeNewsWire

Corbus Pharmaceuticals (CRBP) is up 250%: what's up with the stock?

The stock of Corbus Pharmaceuticals Holdings, Inc. (NASDAQ:CRBP) closed up nearly 250% last week. The gains happened after favourable pharmaceutical news that saw the stock climb above $29.

2 months ago - Invezz

CRB-701 (SYS6002) A Next Generation Nectin-4 Targeting Antibody Drug Conjugate Demonstrates Encouraging Safety and Efficacy in Patients with Nectin-4 Positive Tumors in First-In-Human Study Presented at ASCO-GU 2024

NORWOOD, Mass., Jan. 26, 2024 (GLOBE NEWSWIRE) -- Corbus Pharmaceuticals Holdings, Inc. (NASDAQ: CRBP) (“Corbus” or the “Company”), today announced that data from the first-in-human clinical study of ...

2 months ago - GlobeNewsWire

Phase 1 Clinical Data for SYS6002 (CRB-701) to be presented at 2024 ASCO GU

NORWOOD, Mass., Jan. 23, 2024 (GLOBE NEWSWIRE) -- Corbus Pharmaceuticals Holdings, Inc. (NASDAQ: CRBP) (“Corbus” or the “Company”), announced today that the abstract for the first-in-human Phase 1 dos...

3 months ago - GlobeNewsWire

Corbus Pharmaceuticals Announces FDA Clearance of IND Application for its anti-αvβ8 monoclonal antibody (CRB-601)

NORWOOD, Mass., Jan. 09, 2024 (GLOBE NEWSWIRE) -- Corbus Pharmaceuticals Holdings, Inc. (NASDAQ: CRBP) (“Corbus” or the “Company”), a precision oncology company with a diversified portfolio, today ann...

3 months ago - GlobeNewsWire

Corbus Pharmaceuticals Announces Abstract Accepted for Presentation at 2024 ASCO GU

NORWOOD, Mass., Dec. 18, 2023 (GLOBE NEWSWIRE) -- Corbus Pharmaceuticals Holdings, Inc. (NASDAQ: CRBP) (“Corbus” or the “Company”), a precision oncology company with a diversified portfolio, today ann...

4 months ago - GlobeNewsWire

Corbus Pharmaceuticals Reports Third Quarter 2023 Financial Results and Provides Corporate Update

NORWOOD, Mass., Nov. 07, 2023 (GLOBE NEWSWIRE) -- Corbus Pharmaceuticals Holdings, Inc. (NASDAQ: CRBP) (“Corbus” or the “Company”), a precision oncology company with a diversified portfolio, today pro...

5 months ago - GlobeNewsWire

Corbus Pharmaceuticals Presents Results of Two Pre-Clinical Studies on its Anti-αVβ8 Monoclonal Antibody (CRB-601) at the 2023 SITC Annual Meeting

NORWOOD, Mass., Nov. 02, 2023 (GLOBE NEWSWIRE) -- Corbus Pharmaceuticals Holdings, Inc. (NASDAQ: CRBP) (“Corbus” or the “Company”), a precision oncology company, today announced that results from two ...

5 months ago - GlobeNewsWire

Corbus Pharmaceuticals Announces Publication of Data for its Novel Cannabinoid Type-1 Receptor Inverse Agonist in a Pre-Clinical Model of Obesity Along with Presentations at Obesity Week 2023

NORWOOD, Mass., Oct. 17, 2023 (GLOBE NEWSWIRE) -- Corbus Pharmaceuticals Holdings, Inc. (NASDAQ: CRBP) (“Corbus” or the “Company”), a precision oncology company, today announced results of a pre-clini...

6 months ago - GlobeNewsWire

Corbus Pharmaceuticals Presents the First Pre-Clinical Characterization of its Next Generation Nectin-4 ADC CRB-701

NORWOOD, Mass., Oct. 16, 2023 (GLOBE NEWSWIRE) --  Corbus Pharmaceuticals Holdings, Inc. (NASDAQ: CRBP) (“Corbus” or the “Company”), a precision oncology company, today announced that a poster charact...

6 months ago - GlobeNewsWire

Corbus Pharmaceuticals to Host Virtual ‘Meet the Expert' Series (Session 2) on CRB-701 on October 10, 2023

NORWOOD, Mass., Oct. 03, 2023 (GLOBE NEWSWIRE) -- Corbus Pharmaceuticals Holdings, Inc. (NASDAQ: CRBP) ("Corbus" or the "Company"), a precision oncology company, today announced that it will host a Vi...

7 months ago - GlobeNewsWire

Corbus Pharmaceuticals to Present Latest Pre-Clinical Data on its Anti-aVb8 Monoclonal Antibody (CRB-601) at the 2023 SITC Annual Meeting

NORWOOD, Mass. , Sept. 27, 2023 /PRNewswire/ -- Corbus Pharmaceuticals Holdings, Inc. (NASDAQ: CRBP) ("Corbus" or the "Company"), a precision oncology company, today announced that an abstract highlig...

7 months ago - PRNewsWire

Corbus Pharmaceuticals to Present Pre-Clinical Data Characterizing its CRB-701 Nectin-4 ADC at the at AACR-NCI-EORTC International Conference on Molecular Targets and Cancer Therapeutics

NORWOOD, Mass. , Sept. 19, 2023 /PRNewswire/ -- Corbus Pharmaceuticals Holdings, Inc. (NASDAQ: CRBP) ("Corbus" or the "Company"), a precision oncology company, today announced the pre-clinical data on...

7 months ago - PRNewsWire

Corbus Pharmaceuticals Reports Second Quarter 2023 Financial Results and Provides Corporate Update

CRB-701 Phase 1 trial in China is ahead of schedule with dose escalation completion expected Q4 2023 and U.S. clinical trial start planned for Q1 2024 Preliminary clinical PK data indicates CRB-701 ha...

9 months ago - PRNewsWire

Corbus Pharmaceuticals to Present at the BTIG Virtual Biotechnology Conference

NORWOOD, Mass. , July 31, 2023 /PRNewswire/ -- Corbus Pharmaceuticals Holdings, Inc. (NASDAQ: CRBP) ("Corbus" or the "Company"), a precision oncology company, today announced that Yuval Cohen, Ph.D.

9 months ago - PRNewsWire

Corbus Pharmaceuticals Set to Join Russell Microcap® Index

NORWOOD, Mass. , June 26, 2023 /PRNewswire/ -- Corbus Pharmaceuticals Holdings, Inc. (NASDAQ: CRBP) ("Corbus" or the "Company"), a precision oncology company, today announced that the Company is set t...

10 months ago - PRNewsWire

Corbus Pharmaceuticals to Participate in the 2023 Jefferies Healthcare Conference

NORWOOD, Mass. , May 31, 2023 /PRNewswire/ -- Corbus Pharmaceuticals Holdings, Inc. (NASDAQ: CRBP) ("Corbus" or the "Company"), a precision oncology company, today announced that Yuval Cohen, Ph.D.

11 months ago - PRNewsWire

Corbus Pharmaceuticals Reports First Quarter 2023 Financial Results and Provides Corporate Update

Company expanded precision oncology pipeline with in-licensing of CRB-701: a clinical-stage Nectin-4 antibody drug conjugate (ADC) from CSPC Pharmaceutical Group CRB-701 Phase 1 dose escalation study ...

1 year ago - PRNewsWire